Based on these findings, several irreversible FAAH inhibitors (e.g. BIA 10-2474, PF-04457845, JNJ-42165279) have entered into clinical trials to assess their potential efficacy in patients suffering from major depressive disorder (MDD), social anxiety or post-traumatic stress disorder (PTSD). Here, FAAH is linked to post-traumatic stress disorder.